Increasing prevalence of cardiac diseases, coronary artery diseases, neurodegenerative and infectious diseases are the key factors that are anticipated to fuel the market growth. Antisense and RNAi technologies helps in understanding the mechanism of genes related to turning on and off in cells.RNAi is a gene silencing process in which RNA molecules inhibit the expression of molecule by destructing mRNA. miRNA and siRNA are mainly two types of RNA used in destruction of mRNA. Whereas, antisense therapy involve synthesis of a strand of nucleic acid (DNA or RNA) that would further bind to mRNA and inactivate.RNAi and antisense therapeutics inhibit the gene expression by natural mechanism therefore, the technologies have huge scope for the treatment of various diseases such as neurodegenerative disorders and cancer(colorectal cancer, pancreatic cancer, malignant melanoma, malignant glioma). These technologies are being used majorly by research institutes and pharmaceutical companies.
The antisense and RNAi therapeutics market could be categorized based on therapeutic applications and technology. The therapeutic segment of the market could further be segmented into ocular diseases, infectious diseases, kidney diseases, neurodegenerative diseases, cancer, lung disorder, genetic disorder and respiratory disorder. The RNAi technology could be further analyzed based on siRNA and miRNA. In the therapeutics segment, infectious disease are expected to witness highest growth rate during the forecast period due to rising incidence of infectious disease such as AIDS. The market for antisense and RNAi therapeutics can also be subdivided into different end users such as pharmaceutical industry, therapeutics and research institutes. Presently, research institutes primarily utilize RNA technology for the development of RNA drugs, thereby accounting for the largest market share.
North America, Latin America, Asia Pacific, Europe and MEA are the major geographies for the antisense and RNAi therapeutics market. Currently, North America accounted for the largest market share in terms of revenue generation, due to increasing prevalence of neurodegenerative and cardiovascular disease and increasing awareness among the patient population for the usage of RNA therapeutics. However, Asia Pacific is anticipated to emerge asthefastest growing region in RNAi and antisense therapeutic market because of increasing population base and improving health care facilities.
The antisense and RNAi therapeutics market is witnessing substantial number of strategic collaboration and licensing activities by the pharmaceutical and biotechnological companies. Hence, increasing number of collaboration among the organizations are expected to pull the growth of global antisense and RNAi therapeutics market. Increasing demand for advanced technology for efficient treatment, target specific gene suppression responsible for disease such as Alzheimer disease, Huntington disease and many more.With the usage of RNAi technique synthesis of disease causing protein even before they are made could be inhibited. In 2014,two antisense drugs were approved by the U.S. Food and Drug Administration (FDA) namely Fomivirsen (Vitravene) for the treatment of cytomegalovirus retinitis and Mipomersen (Kynamro) for homozygous familial hypercholesterolemia. Moreover, as of 2014, 40 antisense and siRNA molecules were in clinical trials and in these over 20 drugs were in advance clinical trial (Phase II and III). Thus, presence of large number of RNAi molecules in clinical trials and their expected launch during the forecast period is expected to support the market growth. However, toxicity caused by RNAi and antisense based drugs (primarily liver toxicity) is the major challenge being witnessed by the market. Huge investment and high failure rate are also anticipated to restrain the growth of the industry.
Request for Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4949
Some of the major players operating in antisense and RNAi therapeutics market includes Sanofi S.A., Isis Pharmaceuticals, Tekmira PharmaceuticalsCorporation, AstraZeneca plc, Allergan, Inc., Antisense Therapeutics, Atlantic Pharmaceuticals Inc., Biogen Idec, Ascletis Innovation, Bristol-Myers Squibb, Dainippon SumitomoPharma, GlaxoSmithKline plc, Pfizer, Inc., Novartis AG and Alnylam Pharmaceuticals Inc.
No comments:
Post a Comment